Therapeutic Options for Benign Prostate Hyperplasia (BPH) and Prostatic Cancer
作者： Steve Ken Wing Leung , S. Alan McNeill
关键词:
摘要: The management of symptomatic benign prostate hyperplasia (BPH) includes: Watchful waiting — suitable patients with mild symptoms BPH (International Prostate Symptom Score, IPSS ≤ 7) or moderate severe (IPSS ≥ 8) but minimal bother. Medical therapy bother. Alpha-blockers alfuzosin, tamsulosin, terazosin and doxazosin are similarly effective have quicker onset action. 5α-Reductase inhibitors finasteride dutasteride for lower urinary tract (LUTS) associated demonstrable prostatic enlargement the action is slower. Combination combination alphablocker a 5α-reductase inhibitor in LUTS enlargement. Minimally invasive thermal, radiofrequency laser energy sources used. efficacies these modalities not conclusively proven yet. Surgical who bothersome those developed complications BPH. This may be open endoscopic surgery.
springer.com
springerlink.com参考文章(91)
C.J. Girman, L.A. Panser, C.G. Chute, J.E. Oesterling, D.M. Barrett, C.C. Chen, H.M. Arrighi, H.A. Guess, M.M. Lieber, Natural History of Prostatism: Urinary Flow Rates in A Community-Based Study Journal of Urology. ,vol. 150, pp. 887- 892 ,(1993) , 10.1016/S0022-5347(17)35640-9
Glenn J. Gormley, Elizabeth Stoner, Reginald C. Bruskewitz, Julianne Imperato-McGinley, Patrick C. Walsh, John D. McConnell, Gerald L. Andriole, Jack Geller, Bruce R. Bracken, Joyce S. Tenover, E. Darracott Vaughan, Frances Pappas, Alice Taylor, Bruce Binkowitz, Jennifer Ng, The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. The New England Journal of Medicine. ,vol. 327, pp. 1185- 1191 ,(1992) , 10.1056/NEJM199210223271701
George W. Drach, Terry N. Layton, William J. Binard, Male Peak Urinary Flow Rate: Relationships to Volume Voided and Age The Journal of Urology. ,vol. 122, pp. 210- 214 ,(1979) , 10.1016/S0022-5347(17)56333-8
Patrick C. Walsh, Alan W. Partin, Jonathan I. Epstein, Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years Journal of Urology. ,vol. 152, pp. 1831- 1836 ,(1994) , 10.1016/S0022-5347(17)32396-0
G D Chisholm, R F Deane, G B McKelvie, C D Rennie, E L Gilliland, C P Chilton, M G Royle, N H Townell, J Breakey, S M Cresswell, J Glaholm, G M Sole, J J Bolger, M J Stower, M H Ashken, D A Tolley, F J Bramble, P A Jones, R A Styles, Moffat Lef., R W Glashan, Rhind, A Radley, G J Fellows, J Crowther, B Hafner, S Knight, E Thompson, J Smith, J Burrett, P B Clark, J Boreham, R Peto, L N Jurczyk, B A DeSousa, S Parish, Logie Jrc., Ross Rta., Cox, K Perry, T P Stephenson, K K Sethia, Turner Dtl., M Davies, Harrison Gsm., G F Carswell, Rogers Acn., M Lucas, M R Heal, V Boag, J Hetherington, D Kirk, Charlton Cac., Shepheard Bgf., N A Green, M F Smith, T B Hargreave, Moore Kth., R J Morgan, K N Bullock, Bevis Cra., J B Anderson, A L Stewart, Newling Dwk., B Richards, Grayson Cea., Gaches Cgc., P T Doyle, Robinson Mrg., S Sagar, R J Shearer, C M Evans, R A Jones, Wightman Jak., E R Coulton, J C Smith, M E French, C S Powell, Fernie Cgm., Orr Pgg., M Claridge, Gallegos Crr., G H Urwin, G M Watson, C Roberts, S Griffin, M B Rose, M Fordham, G S Watson, W T Lawrence, R Pollard, P H Smith, M J James, Grant Jbp., J P Ward, R R Hall, M Hehir, J L Williams, R W Thomson, L L Beynon, R J Luck, R Rampling, R S Adib, P English, A McGregor, C D Baumber, J W Blaxland, M H Devereux, R Clack, Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial BJUI. ,vol. 79, pp. 235- 246 ,(1997)
F H Schröder, L Collette, T M de Reijke, P Whelan, Prostate cancer treated by anti-androgens: is sexual function preserved? British Journal of Cancer. ,vol. 82, pp. 283- 290 ,(2000) , 10.1054/BJOC.1999.0916
John T. Isaacs, Hugh F. English, Natasha Kyprianou, Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Research. ,vol. 50, pp. 3748- 3753 ,(1990)
I F Tannock, D Osoba, M R Stockler, D S Ernst, A J Neville, M J Moore, G R Armitage, J J Wilson, P M Venner, C M Coppin, K C Murphy, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology. ,vol. 14, pp. 1756- 1764 ,(1996) , 10.1200/JCO.1996.14.6.1756
Anita R Sgrignoli, Patrick C Walsh, Gary D Steinberg, Mitchell S Steiner, Jonathan I Epstein, None, Prognostic Factors in Men with Stage D1 Prostate Cancer: Identification of Patients Less Likely to Have Prolonged Survival After Radical Prostatectomy Journal of Urology. ,vol. 152, pp. 1077- 1081 ,(1994) , 10.1016/S0022-5347(17)32507-7
A. Decensi, D. Guarneri, M.C. Paoletti, J.M. Lalanne, F. Merlo, F. Boccardo, Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer European Journal of Cancer and Clinical Oncology. ,vol. 27, pp. 1100- 1104 ,(1991) , 10.1016/0277-5379(91)90301-S